ARRAY BIOPHARMA INC Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2018 12 months to Jun 30, 2018	FY2017 12 months to Jun 30, 2017	FY2016 12 months to Jun 30, 2016	FY2015 12 months to Jun 30, 2015	FY2014 12 months to Jun 30, 2014
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense
Non-cash interest expense
Share-based compensation expense
Extinguishment of co-development liability, net
Loss on extinguishment and conversion of Notes
Payment of employee bonus with stock
Realized gain from investments, net
Gain on sale of CMC, net
Non-cash license revenue
Impairment loss related to cost method investment
Financing fees on notes payable
Senior notes
Total financing fees on notes payable
Change in fair value of notes payable
Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses and other assets
Accounts payable and other accrued expenses
Accrued outsourcing costs
Accrued compensation and benefits
Co-development liability
Deferred rent
Deferred revenue
Other long-term liabilities

Net cash used in operating activities
Cash flows from investing activities
Purchases of property and equipment
Proceeds from investment
Proceeds from sale of CMC
Purchases of marketable securities
Proceeds from sales and maturities of marketable securities
Net cash provided by (used in) investing activities
Cash flows from financing activities
Net proceeds from the issuance of common stock
Public offering
At-the-market offering
Total net proceeds from the issuance of common stock
Proceeds from notes payable at fair value
Proceeds from employee stock purchases and options exercised
Payment of debt issuance costs
Notes Payable
Senior notes
Total payment of debt issuance costs
Payment of Comerica term loan
Proceeds from the issuance of the SVB term loan
Warrants exercised for cash
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure of cash flow information
Cash paid for interest
Cash paid for income taxes
Change in unrealized gain (loss) on marketable securities

Comments